Trastuzumab emtansine
- Generic Name
- Trastuzumab emtansine
- Brand Names
- Kadcyla
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1018448-65-1
- Unique Ingredient Identifier
- SE2KH7T06F
- Background
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine deriva...
- Indication
Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
- Associated Conditions
- HER2-Positive Early Stage Breast Cancer, HER2-positive, Metastatic Breast Cancer
- Associated Therapies
- -
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 216
- Registration Number
- NCT04398914
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Ulrik Lassen
- Target Recruit Count
- 300
- Registration Number
- NCT04341181
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT04298918
- Locations
- 🇦🇺
Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- xuexin he
- Target Recruit Count
- 130
- Registration Number
- NCT04158947
- Locations
- 🇨🇳
Peking University International Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China
🇨🇳Kiang Wu Hospital, Macao, Macao, China
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 2
- Registration Number
- NCT04042051
- Locations
- 🇪🇸
Cancer Trials Ireland Investigative Site, Seville, Spain
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT03975647
- Locations
- 🇺🇸
Texas Oncology - Medical City Dallas, Dallas, Texas, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Renske Altena
- Target Recruit Count
- 6
- Registration Number
- NCT03894007
- Locations
- 🇸🇪
Sahlgrenska universitetssjukhuset, Göteborg, Sweden
🇸🇪Skånes universitetssjukhus, Malmö, Sweden
🇸🇪Länssjukhuset Sundsvall, Sundsvall, Sweden
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT03784599
- Locations
- 🇳🇱
Univercity Medical Center Groningen, Groningen, Netherlands
🇳🇱Maastricht UMC+, Maastricht, Limburg, Netherlands
🇳🇱Antoni van Leeuwenhoek ziekenhuis - Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 454
- Registration Number
- NCT03726879
- Locations
- 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT03709082
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
🇺🇸The University of Kansas Cancer Center, West Clinic, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.